San Rocco reports manufacturing progress for MiNiRoLu gene therapy
San Rocco Therapeutics says new data presented at the 2026 ESGCT congress in Hamburg support advancement of its lead investigational gene therapy for sickle cell disease and beta-thalassemia. The company plans an initial U.S. trial at the NIH, followed by European development in Italy.
Why it matters: - San Rocco Therapeutics is trying to move SRT8, also known as MiNiRoLu, toward clinical testing for sickle cell disease and beta-thalassemia. - The new data center on manufacturing and therapeutic protein expression, two hurdles that can slow gene therapy programs before patient studies begin. - The company’s stated goal is to make one-time gene therapy products more affordable and accessible if development succeeds.
What happened: - San Rocco Therapeutics announced progress toward clinical development of SRT8 after presenting data at the 2026 Annual Congress of the European Society of Gene and Cell Therapy in Hamburg, Germany. - Dr. Frank Park of the University of Tennessee Health Science Center presented the findings in a talk titled “A GMP Manufacturing Protocol for a T87Q β-Globin Drug Product to Treat β-Hemoglobinopathies.” - The presentation covered manufacturing, vector stability, gene transfer efficiency, and therapeutic gene and protein expression. - Park is also the acting chief scientific officer of San Rocco Therapeutics’ European subsidiary.
The details: - SRT8 is designed to address the genetic cause of sickle cell disease and beta-thalassemia by adding a therapeutic β-globin gene to a patient’s own blood-forming stem cells. - The research showed production of a high-titer, GMP-grade self-inactivating lentiviral vector with stability greater than 18 months. - The team reported efficient modification of primary human hematopoietic stem cells at low vector doses, with multiplicity of infection levels of 25 to 75. - Those cells produced T87Q β-globin protein at levels above those previously reported for Bluebird bio’s BB305 platform. - The researchers also quantified T87Q β-globin mRNA using a novel variant-specific RT-PCR assay. - San Rocco said the advances represent a milestone toward producing genetically modified, autologous hematopoietic stem cells for therapeutic use. - MiNiRoLu remains an investigational gene therapy. - Clinical validation studies are intended to assess safety and efficacy in patients with sickle cell disease or beta-thalassemia.
Between the lines: - The results suggest San Rocco is focusing first on manufacturing readiness, not just biological activity. - Strong vector stability and higher protein expression can help de-risk later-stage development, although they do not prove clinical benefit. - The comparison with Bluebird bio’s BB305 platform signals that San Rocco is positioning SRT8 as a potentially competitive approach in hemoglobinopathy gene therapy.
What’s next: - San Rocco plans a phased clinical strategy with initial trials at the National Institutes of Health. - The company then expects European testing and development in Italy. - The next major test will be whether the manufacturing progress translates into safety and efficacy in patients. - San Rocco says it remains committed to long-term affordable access for the therapy if development advances.
The bottom line: - San Rocco is moving MiNiRoLu from lab work toward human testing, with the newest data aimed at showing the program can be manufactured and expressed at levels that support clinical development.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Industry Times Tennessee
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.